ANN assists physicians in diagnosing stroke patients

Researchers from the Nutritional Immunology and Molecular Medicine Laboratory and the Department of Biomedical and Translational Informatics at Geisinger Health System teamed up to develop an artificial neural network (ANN) model to accurately recognize stoke symptoms.

The artificial intelligence (AI) model utilizes millions of data points provided by Geisinger Health System to precisely identify, prevent and treat stroke based on a patient's personalized health record. By accurately identifying stoke patients as the enter the emergency room, the model has the potential to be a new data-driven method of improving patient outcomes.

“Advanced machine-learning methods will be driving the next generation of personalized medicine at the clinical and genomic levels; however, these methods and their outcomes will have an added value if we let models actively learn from experts and experts learn from models. Our team has applied AI successfully to develop a data-driven triage process for classifying stroke patients. Ongoing collaborative studies are also applying these same AI methods successfully in infectious and immune-mediated diseases,” said Vida Abedi, a researcher at Geisinger Health System and adjunct faculty member in NIMML.

The study enrolled 260 patients who visited the emergency room with stroke-like symptoms, within 4.5 hours of onset. The ANN model showed 80 percent sensitivity and 86.2 percent specificity, proving an effective tool in identify stroke patients.

""
Cara Livernois, News Writer

Cara joined TriMed Media in 2016 and is currently a Senior Writer for Clinical Innovation & Technology. Originating from Detroit, Michigan, she holds a Bachelors in Health Communications from Grand Valley State University.

Around the web

The tirzepatide shortage that first began in 2022 has been resolved. Drug companies distributing compounded versions of the popular drug now have two to three more months to distribute their remaining supply.

The 24 members of the House Task Force on AI—12 reps from each party—have posted a 253-page report detailing their bipartisan vision for encouraging innovation while minimizing risks. 

Merck sent Hansoh Pharma, a Chinese biopharmaceutical company, an upfront payment of $112 million to license a new investigational GLP-1 receptor agonist. There could be many more payments to come if certain milestones are met.